SCHEMBL6289367

SCHEMBL6289367

CN1C(=O)C(Cc2ccc(F)cc2)C(=O)c2oc(C#CCc3ccccc3)cc21

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.38
KDM4C Q9H3R0 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MMP13 P45452 1/20 0.35
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPT P10636 1/20 0.33
LMNA P02545 1/20 0.32
PARK7 Q99497 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
MDM2 Q00987 2/20 0.31
BRD4 O60885 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CTSB P07858 1/20 0.31
CTSS P25774 1/20 0.31
ATM Q13315 1/20 0.31
GAA P10253 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292799 0.78 CES2 (0.38) CES2KDM4CMEN1KMT2AMMP13
SCHEMBL6288765 0.77 HPGD (0.47) MEN1KMT2AALDH1A1HSD17B10MAPT
SCHEMBL6289332 0.74 ALDH1A1 (0.34) CES2KDM4CMEN1KMT2AALDH1A1
SCHEMBL6288803 0.67 KDM4C (0.33) CES2KDM4CMEN1KMT2AMMP13
SCHEMBL6288801 0.67 MAPT (0.37) CES2MEN1KMT2AMMP13ALDH1A1
SCHEMBL6699545 0.67 MMP13 (0.39) MMP13ALDH1A1MAPTLMNANPSR1
SCHEMBL6292839 0.65 MMP13 (0.38) MEN1KMT2AMMP13MAPTLMNA
SCHEMBL6292732 0.65 GPR55 (0.36) MEN1KMT2AMMP13MAPTLMNA
SCHEMBL17070921 0.65 KDM4E (0.69) CES2KDM4CMEN1KMT2AALDH1A1
SCHEMBL6288744 0.65 KDM4C (0.34) CES2KDM4CMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 CES2 1671/4885KDM4C 1177/4885MEN1 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.